Unity Biotechnology suffers setback for lead drug candidate UBX0101
Unity Biotechnology Inc. (UBX) reported its 12-week data from Phase 2 clinical study in patients with painful osteoarthritis of the knee. The data did not show any statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline. The change was measured using WOMAC-A which is a standard measurement of pain in osteoarthritis. The company has decided not to progress the drug candidate into pivotal studies. UNITY has also decided to focus on its ophthalmologic and neurologic